Literature DB >> 3745970

Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients.

A Alberti, P Pontisso, G Fattovich, E Schiavon, L Chemello, F Bortolotti, F Tremolada, G Realdi.   

Abstract

In an assessment of the clinical relevance of serum hepatitis B virus (HBV) DNA testing in chronic HBV infection, changes in the presence of this marker were investigated by spot hybridization in 138 hepatitis B surface antigen (HBsAg)-positive patients with chronic liver disease who were followed up for one to eight years. Forty-one patients were treated with steroids, often with evidence of potentiation of viral replication, whereas 92 patients remained untreated and had no evidence of sigma agent infection during follow-up. Data analysis in these patients allowed us to determine the significance of testing for hepatitis B e antigen and for HBV DNA in the natural history of the infection. The findings indicate that sequential testing for serum HBV DNA may be of great importance in HBsAg chronic carriers with liver disease for adequate evaluation of HBV replication and for the contribution of HBV DNA to the clinical assessment of chronic hepatitis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3745970     DOI: 10.1093/infdis/154.4.562

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

Review 1.  Treatment of chronic hepatitis B: new antiviral therapies.

Authors:  F Yao; R G Gish
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

2.  Natural history and prognostic factors for chronic hepatitis type B.

Authors:  G Fattovich; L Brollo; G Giustina; F Noventa; P Pontisso; A Alberti; G Realdi; A Ruol
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

3.  Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy.

Authors:  Norio Akuta; Fumitaka Suzuki; Akihito Tsubota; Yasuji Arase; Yoshiyuki Suzuki; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Kenji Ikeda; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

4.  A randomized, double-blind, controlled trial of natural interferon-beta therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels.

Authors:  Y Arase; K Chayama; A Tsubota; N Murashima; Y Suzuki; I Koida; M Kobayashi; S Saitoh; K Ikeda; H Kumada; M Kobayashi; H Suzuki
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

5.  Definition of hepatitis B virus (HBV)-specific target antigens recognized by cytotoxic T cells in acute HBV infection.

Authors:  M U Mondelli; F Bortolotti; P Pontisso; E G Rondanelli; R Williams; G Realdi; A Alberti; A L Eddleston
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

6.  One year of Lamivudine therapy for portuguese patients with chronic hepatitis B.

Authors:  J Areias; F Calinas; A Porto; A Carvalho; D Freitas; G Macedo; R Noronha; J Cotter; A Meliço-Silvestre; R Peixe; J Pratas; D Barrote; R Teixeira; F Augusto; I Carrilho; F Campante; J Velosa; L Carvalho; M A Duarte; H Guerreiro; C Pires; A Silva; I Cotrim; F Guedes; L Tomé; M Marcelino; C Gonçalves; E Ferreira; L Matos; P Peixe; J Esteves; T Valente; C Simões; C Marinho; L Jasmins; M J Vieira; R Marinho; P Matos; J Estevens; J Carrasquinho; G Salcedo; P Parada; C Teixeira
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.